全产业链生态激发生物医药创新活力 ——探访北京昌平“生命谷”

Core Viewpoint - The 42nd National Pharmaceutical Industry Information Annual Conference highlighted the innovative achievements and industrial ecosystem in Changping District, focusing on areas such as innovative drugs, synthetic biology, and medical devices [1] Group 1: Industry Development - Changping District is home to the Zhongguancun Life Science Park, covering approximately 7.2 square kilometers, which hosts over 800 innovative pharmaceutical companies and high-level research institutions [1] - The district's pharmaceutical health enterprises achieved revenues of 33.79 billion yuan from January to April, representing a year-on-year growth of 15.1%, and a total output value of 17.07 billion yuan from January to May, with an 8.8% increase [7] Group 2: Precision Medicine - The Life Valley International Precision Medicine Industrial Park, a key project in the Zhongguancun Life Science Park, focuses on precision diagnosis, targeted therapy, and immunotherapy, aiming to enhance the integration of research, industry, and education [2] - The park covers a total construction area of 240,000 square meters and aims to create an ecosystem that supports the entire process from research incubation to product acceleration and mass production [2] Group 3: Research and Innovation - The Beijing Brain Science and Brain-like Research Institute has established 11 international first-class technology platforms and published 362 papers in top journals, showcasing its strong research capabilities [3] - The institute's "North Brain No. 1" intelligent brain-machine system is the first semi-invasive system with over 100 channels, currently undergoing clinical trials for various neurological disorders [3] Group 4: Company Highlights - Innovent Biologics has developed significant drugs such as Orelabrutinib, the first BTK inhibitor approved for marginal zone lymphoma in China, and has a rich pipeline including a new generation TRK inhibitor [4] - The Beijing Darts International Innovation Center has supported over 60 biopharmaceutical projects, raising over 3 billion yuan in financing and obtaining more than 300 intellectual property rights [6] Group 5: Ecosystem and Collaboration - The Changping District is fostering a comprehensive ecosystem for advanced therapy medicinal products (ATMPs) with strong support from leading CDMO companies like Yiming Biotechnology, which has established multiple production bases and achieved significant milestones in IND applications [6] - The district aims to enhance international compliance levels for local pharmaceutical companies and contribute to the global competitiveness of China's biopharmaceutical industry [6]